NEW YORK, Jan. 06, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of TG Therapeutics, Inc. (“TGTX”) (NASDAQ:TGTX) between September 15, 2014 and October 12, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/tg-therapeutics
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, TGTX misrepresented and/or omitted material information concerning its GENUINE Phase III clinical trial for its proprietary combination of drug therapies TG-1101 and TGR-1202. The Phase III trial consisted of two parts, Part I evaluating the effect of the addition of TG-1101 to ibrutinib on overall response rate (ORR) in approximately 200 patients, and Part II evaluating the effect of the addition of TG-1101 to ibrutinib on progression-free survival (PFS) in all study patients.
During the class period TGTX repeatedly assured investors as to the efficacy and potential FDA approval of the treatment, referring to it as a “best-in-class treatment.” Then on October 13, 2016, TGTX announced that it would abandon Part II of the study, thus annulling its filed Special Protocol Assessment with the FDA and cutting enrollment and increasing the likelihood that the FDA would not approve the combination treatment.
If you suffered a loss in TGTX you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 



